MedTrace Logo

Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections

NCT06387667 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-08-14

No results posted yet for this study

Summary

Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.

Conditions

  • Immunocompromised ICU Patients With Respiratory Tract Infections

Interventions

DIAGNOSTIC_TEST

Complete blood count

blood sample

DIAGNOSTIC_TEST

C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)

serum sample

RADIATION

CT chest

Computed tomography of the chest

DIAGNOSTIC_TEST

Microscopic examination

sputum and bronchoalveolar lavage (BAL)

DIAGNOSTIC_TEST

culture and sensitivity

for bacterial and fungal

Sponsors & Collaborators

  • New Valley University

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-12-01
Completion
2027-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06387667 on ClinicalTrials.gov